All News

The FDA has granted a full approval to pembrolizumab for the treatment of platinum-ineligible patients with urothelial cancer.

Compared with anti-thymocyte globulin, post-transplant cyclophosphamide appears to more successfully prevent graft-versus-host disease in patients with acute lymphoblastic leukemia, resulting in a lower incidence of relapse and improved survival.

Low study quality was determined in an analysis of real-world studies across multiple drug indications in cancer.

Survivorship incorporated into primary cancer care may be more cost effective and lead to better clinical and patient-reported outcomes in patients with breast cancer and other malignancies.

A new set of guidelines for utilizing radiation therapy in adult patients with soft tissue sarcoma has been published by the American Society for Radiation Oncology.

Patients with relapsed or regractory B-cell malignancies who were treated with zanubrutinib and zandelisib demonstrated high response rates across several treatment cohorts.

Patients with non–small cell lung cancer and small-cell lung cancer with bone metastases may benefit from extended dosing with zoledronic acid.

Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.

Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.

Patients with high-risk early breast cancer who received zoledronate for over 2 years did not experience an improvement in prognosis.

Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.

The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.

This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.

Responses to a cross-sectional survey brought to light disparities through important aspects of diagnosing and treating brain metastases.

CancerNetwork® spoke with Quita Highsmith and Monica Baskin, MD, about the Advancing Inclusive Research Alliance and efforts to include more diverse populations in clinical trials.

Atezolizumab will no longer be available for the treatment of patients with PD-L1–positive triple-negative breast cancer following withdrawal of the indication by the agent’s developer.

Geriatric patients with prostate cancer did not experience a decline in cognative function regardless of treatment.

The phase 2 CAVE trial indicated that a combination of cetuximab and avelumab is a promising rechallenge treatment for patients with RAS wild-type metastatic colorectal cancer.

Patients with hematologic malignancies may be at a higher risk for breakthrough infections following full COVID-19 vaccination.

An oncology pharmacist speaks about the occurance of left ventricular dysfunction noted with margetuximab in the treatment of HER2-positive metastatic breast cancer.

Low-dose rotational total skin electron beam therapy helped to improve skin-related quality of life and yielded promising responses among patients with mycosis fungoides.

An oncology pharmacist talks infusion-related reactions with margetuximab in the treatment of HER2-positive metastatic breast cancer.

Oncomine Dx Target Test is now approved by the FDA as a companion diagnostic for patients with IDH1-mutant cholangiocarcinoma who may be candidates for treatment with ivosidenib.

A novel imaging technique using the folate analog tracer FA-S0456 was able to detect small, nonpalpable lung lesions otherwise undetectable by traditional means during resection surgery.

Patients with myelodysplastic syndromes showed favorable event-free survival with allogeneic stem cell transplant compared with those being treated with continuous 5-azacytidine.

Ivosidenib has received approval from the FDA for patients with IDH1-mutated cholangiocarcinoma.

Researchers utilized a ctDNA assay to evaluate minimal residual disease in patients with multiple myeloma post-autologous stem cell transplantation.

Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer.

Tebentafusp has demonstrated promising responses in metastatic uveal melanoma, leading to FDA and European Medicines Agency approval of a biologics license application and marketing authorization application for the agent.

Women who received a total abdominal hysterectomy plus chemotherapy showed better survival then those women who received chemotherapy alone for uterine cancer with distant organ metastasis.